Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/28444
Title: Correction: Phase 1A/1B dose-escalation and -expansion study to evaluate the safety, pharmacokinetics, food effects and antitumor activity of pamiparib in advanced solid tumours.
Austin Authors: Lickliter, Jason D;Voskoboynik, Mark;Mileshkin, Linda;Gan, Hui K ;Kichenadasse, Ganessan;Zhang, Kathy;Zhang, Maggie;Tang, Zhiyu;Millward, Michael
Affiliation: Medicine (University of Melbourne)
Olivia Newton-John Cancer Wellness and Research Centre
Peter MacCallum Cancer Centre-East Melbourne, East Melbourne, VIC, Australia
La Trobe University School of Cancer Medicine, Heidelberg, VIC, Australia
Central Clinical School, Monash University, Melbourne, VIC, Australia
Flinders Centre for Innovation in Cancer, Flinders Medical Centre, Bedford Park, SA, Australia
Linear Clinical Research & University of Western Australia, Nedlands, WA, Australia
BeiGene USA, Inc., San Mateo, CA, USA
Nucleus Network, Melbourne, VIC, Australia
Issue Date: Feb-2022
Date: 2021
Publication information: British Journal of Cancer 2021; 126(2): 310.
URI: https://ahro.austin.org.au/austinjspui/handle/1/28444
DOI: 10.1038/s41416-021-01671-9
ORCID: 0000-0001-9923-5149
0000-0002-1744-1617
0000-0001-7319-8546
Journal: British Journal of Cancer
PubMed URL: 34931042
PubMed URL: https://pubmed.ncbi.nlm.nih.gov/34931042/
Type: Journal Article
Appears in Collections:Journal articles

Show full item record

Page view(s)

18
checked on Oct 5, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.